Vagus nerve stimulation for cardiovascular diseases: Is there light at the end of the tunnel?

Atrial fibrillation Bioelectronic medicine Cardiovascular disease Heart failure Hypertension Pulmonary hypertension Vagus nerve stimulation

Journal

Trends in cardiovascular medicine
ISSN: 1873-2615
Titre abrégé: Trends Cardiovasc Med
Pays: United States
ID NLM: 9108337

Informations de publication

Date de publication:
26 Jul 2023
Historique:
received: 16 05 2023
revised: 12 06 2023
accepted: 17 07 2023
pubmed: 29 7 2023
medline: 29 7 2023
entrez: 28 7 2023
Statut: aheadofprint

Résumé

Autonomic dysfunction and chronic inflammation contribute to the pathogenesis and progression of several cardiovascular diseases (CVD), such as heart failure with preserved ejection fraction, atherosclerotic CVD, pulmonary arterial hypertension, and atrial fibrillation. The vagus nerve provides parasympathetic innervation to the heart, vessels, and lungs, and is also implicated in the neural control of inflammation through a neuroimmune pathway involving the spleen. Stimulation of the vagus nerve (VNS) can in principle restore autonomic balance and suppress inflammation, with potential therapeutic benefits in these diseases. Although VNS ameliorated CVD in several animal models, early human studies have demonstrated variable efficacy. The purpose of this review is to discuss the rationale behind the use of VNS in the treatment of CVD, to critically review animal and human studies of VNS in CVD, and to propose possible means to overcome the challenges in the clinical translation of VNS in CVD.

Identifiants

pubmed: 37506989
pii: S1050-1738(23)00064-6
doi: 10.1016/j.tcm.2023.07.003
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Correctly acknowledging the primary funders and grant IDs of your research is important to ensure compliance with funder policies. Please make sure that funders are mentioned accordingly.

Auteurs

Stefanos Zafeiropoulos (S)

Elmezzi Graduate School of Molecular Medicine at Northwell Health, Manhasset, NY, USA; Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA.

Umair Ahmed (U)

Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA.

Alexia Bikou (A)

Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA.

Ibrahim T Mughrabi (IT)

Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA.

Stavros Stavrakis (S)

Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Stavros Zanos (S)

Elmezzi Graduate School of Molecular Medicine at Northwell Health, Manhasset, NY, USA; Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, USA. Electronic address: szanos@northwell.edu.

Classifications MeSH